×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AVIR – atea pharmaceuticals, inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AVIR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/2
06:16 am
avir
Atea Pharmaceuticals (NASDAQ:AVIR) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Low
Report
Atea Pharmaceuticals (NASDAQ:AVIR) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
11/19
08:26 pm
avir
Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... [Yahoo! Finance]
Medium
Report
Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... [Yahoo! Finance]
11/19
07:00 am
avir
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
Medium
Report
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
11/13
02:33 pm
avir
Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements Transcript [Seeking Alpha]
Low
Report
Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements Transcript [Seeking Alpha]
11/12
07:03 pm
avir
Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
04:36 pm
avir
Atea Pharmaceuticals GAAP EPS of -$0.53 misses by $0.09 [Seeking Alpha]
High
Report
Atea Pharmaceuticals GAAP EPS of -$0.53 misses by $0.09 [Seeking Alpha]
11/12
04:05 pm
avir
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
11/7
08:00 am
avir
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
Low
Report
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2025
04:05 pm
avir
atea pharmaceuticals, inc. - common stock
MISS
Report
-12.0%
atea pharmaceuticals, inc. - common stock
8/7/2025
04:05 pm
avir
atea pharmaceuticals, inc. - common stock
BEAT
Report
-2.3%
atea pharmaceuticals, inc. - common stock
5/12/2025
04:11 pm
avir
atea pharmaceuticals, inc. - common stock
BEAT
Report
-11.1%
atea pharmaceuticals, inc. - common stock
3/6/2025
04:05 pm
avir
atea pharmaceuticals, inc. - common stock
MISS
Report
-0.3%
atea pharmaceuticals, inc. - common stock
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/7
Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc.
20.6%
1/12 Form 8-K Aviragen Therapeutics, For: Jan 11 13.6%
11/29 Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma 10.2%
1/17 Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc. 4.8%
11/7 Form 10-Q Aviragen Therapeutics, For: Sep 30 3.8%
2/6 Form 8-K Aviragen Therapeutics, For: Feb 06 3.3%
1/3 Form 424B3 Aviragen Therapeutics, 2.7%
2/7 Aviragen and Vaxart Amend Terms of Merger Agreement to Increase the Value for Aviragen Stockholders 2.0%
11/6 Aviragen Therapeutics, Inc. (NASDAQ: AVIR) had its "hold" rating re-affirmed by analysts at HC Wainwright. 1.8%
12/12 Form S-4 Aviragen Therapeutics, 1.7%
1/12 Form 8-K Aviragen Therapeutics, For: Jan 11 13.6%
11/29 Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma 10.2%
1/17 Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc. 4.8%
11/7 Form 10-Q Aviragen Therapeutics, For: Sep 30 3.8%
2/6 Form 8-K Aviragen Therapeutics, For: Feb 06 3.3%
1/3 Form 424B3 Aviragen Therapeutics, 2.7%
2/7 Aviragen and Vaxart Amend Terms of Merger Agreement to Increase the Value for Aviragen Stockholders 2.0%
11/6 Aviragen Therapeutics, Inc. (NASDAQ: AVIR) had its "hold" rating re-affirmed by analysts at HC Wainwright. 1.8%
12/12 Form S-4 Aviragen Therapeutics, 1.7%
TOP News Decliners
2/13
Form SC 13G/A Aviragen Therapeutics, Filed by: Broadfin Capital, LLC
-8.7%
2/9 BRIEF-Aviragen Adjourns Special Meeting Of Stockholders [Reuters] -7.3%
2/1 Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc. -7.1%
2/6 Aviragen Adjourns Special Meeting of Stockholders Until February 9, 2018 -6.0%
12/29 Form SC 13D Aviragen Therapeutics, Filed by: DIGIRAD CORP -5.2%
1/29 Form DFAN14A Aviragen Therapeutics, Filed by: DIGIRAD CORP -4.7%
1/12 Form PREC14A Aviragen Therapeutics, Filed by: DIGIRAD CORP -4.4%
1/18 Form SC 13D/A Aviragen Therapeutics, Filed by: SC Fundamental Value Fund, L.P. -4.3%
1/24 Form DFAN14A Aviragen Therapeutics, Filed by: DIGIRAD CORP -3.0%
11/9 Form SC 13D/A Aviragen Therapeutics, Filed by: SC Fundamental Value Fund, L.P. -2.7%
2/9 BRIEF-Aviragen Adjourns Special Meeting Of Stockholders [Reuters] -7.3%
2/1 Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc. -7.1%
2/6 Aviragen Adjourns Special Meeting of Stockholders Until February 9, 2018 -6.0%
12/29 Form SC 13D Aviragen Therapeutics, Filed by: DIGIRAD CORP -5.2%
1/29 Form DFAN14A Aviragen Therapeutics, Filed by: DIGIRAD CORP -4.7%
1/12 Form PREC14A Aviragen Therapeutics, Filed by: DIGIRAD CORP -4.4%
1/18 Form SC 13D/A Aviragen Therapeutics, Filed by: SC Fundamental Value Fund, L.P. -4.3%
1/24 Form DFAN14A Aviragen Therapeutics, Filed by: DIGIRAD CORP -3.0%
11/9 Form SC 13D/A Aviragen Therapeutics, Filed by: SC Fundamental Value Fund, L.P. -2.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: